Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 23.02.2022
Aspermont Ltd.
Record FY results 2021 - 65% Gross Profit Margin - Profitable & scalable
XaaS model
First FY posting positive net profit after tax. The Company long term
strategy put in force a few years ago has delivered as promised.
Strongest FY cash position. The Company has over $7M cash on hand.
Highest FY Gross Margin. The Company's Gross Margin h [ … ]
Wed, 16.02.2022
CENIT AG
As expected, the excellent development of the fourth quarter of 2021
contributed significantly to the successful business development of CENIT
AG in the past business year 2021. With sales revenues in an expected range
of EUR 153 - 155 million, an EBIT of EUR 6.0 - 6.3 million should have been
achieved. Both the turnover and in particular the resu [ … ]
Tue, 15.02.2022
Aspermont Limited
Upcoming Investor Event:
Aspermont to present at digital International Investment Forum (IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Aspermont Ltd. will also present its business model and current
business development.
Presentation slot:
Aspermont Ltd. (ISIN: AU000000ASP3)
04.00 am EST (New Yor [ … ]
Tue, 15.02.2022
Defence Therapeutics Inc.
Einzigartig positioniert mit vielseitigem ACCUM(TM); Enormes
Aufwärtspotenzial; Die nächste Generation der Krebsbehandlung
- Proprietäre Plattformtechnologie mit nachweislich verbesserter
intrazellulärer Verabreichung. Fördert die Bereitstellung des
Zielprodukts ohne unspezifischen Protein-/Antigenabbau oder
[ … ]
Mon, 14.02.2022
Defence Therapeutics Inc.
Upcoming Investor Event:
Defence Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Defence Therapeutics Inc. will also present its business model
and current business development.
Presentation slot:
Defence Therapeutics Inc.
08.00 am [ … ]
Sat, 12.02.2022
Cogia AG
Upcoming Investor Event:
Cogia to present at digital International Investment Forum (IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Cogia AG will also present its business model and current
business development.
Presentation slot:
Cogia AG (ISIN: DE000A3H2226)
10.30 am EST (New York, Toronto time) [ … ]
Fri, 11.02.2022
Saturn Oil & Gas Inc.
Upcoming Investor Event:
Saturn Oil + Gas to present at digital International Investment Forum (IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Saturn Oil + Gas will also present its business model and
current business development.
Presentation slot:
Saturn Oil + Gas Inc. (ISIN: CA80412L8832)
11.15 [ … ]
Thu, 10.02.2022
Advanced Blockchain AG
Advanced Blockchain AG is a venture builder and investor in the blockchain
ecosystem equipped with a comprehensive team of researchers, developers,
auditors, economists, and mathematicians dedicated to engineering the
future of Web 3.0.
GBC AG: Hello Mr. Geike, can you give me a quick rundown of your company,
your business model, and your strate [ … ]
Thu, 10.02.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14161Y2 [ … ]
Thu, 10.02.2022
Defence Therapeutics Inc.
Uniquely Positioned with versatile ACCUM(TM); Enormous upside potential;
Next generation of cancer treatment
- Proprietary platform technology with proven enhanced intracellular
delivery. Promotes delivery of target product without non-specific
protein/antigen degradation or interference.
- Strong versatility of the Accum(TM) platf [ … ]
